Sign In
Buy AEMD
$1.36
-0.0200 (-1.45%)
At Close: Jun 23, 2026
SAN DIEGO , Dec. 5, 2025 /PRNewswire/ -- Aethlon Medical, Inc. ("Aethlon" or the "Company") (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threat
Results Support the Further Investigation of the Hemopurifier in Long COVID SAN DIEGO , Dec. 2, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on deve
Aethlon Medical, Inc. (AEMD) Q2 2026 Earnings Call Transcript
06:31pm, Wednesday, 12'th Nov 2025
Aethlon Medical, Inc. ( AEMD ) Q2 2026 Earnings Call November 12, 2025 4:30 PM EST Company Participants James Frakes - CEO, CFO, Chief Accounting Officer, Secretary & Director Steven Larosa - Chief Me
Aethlon Medical Announces Fiscal Q2 2025 Financial Results and Corporate Update
04:15pm, Wednesday, 12'th Nov 2025
Clinical and research progress continues alongside substantial cost reductions. Conference Call Today at 4:30 p.m.
Aethlon Medical to Release Fiscal Second Quarter Financial Results and Host Conference Call on November 12, 2025
08:01am, Friday, 07'th Nov 2025
SAN DIEGO , Nov. 7, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, to
SAN DIEGO , Oct. 7, 2025 /PRNewswire/ -- Aethlon Medical, Inc. ("Aethlon" or the "Company") (Nasdaq: AEMD) today provided observations on the preliminary changes in extracellular vesicle (EV), microRN
Aethlon Medical Announces Pricing of $4.5 Million Public Offering
09:15am, Thursday, 04'th Sep 2025
SAN DIEGO , Sept. 4, 2025 /PRNewswire/ -- Aethlon Medical, Inc. ("Aethlon" or the "Company") (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threa
Aethlon Medical, Inc. (AEMD) Q1 2026 Earnings Call Transcript
08:01pm, Wednesday, 13'th Aug 2025
Aethlon Medical, Inc. (NASDAQ:AEMD ) Q1 2026 Earnings Conference Call August 13, 2025 4:30 PM ET Company Participants James B. Frakes - CEO, CFO, Secretary & Director Steven P.
Aethlon Medical Announces Financial Results for the Fiscal First Quarter Ended June 30, 2025, and Provides Corporate Update
04:15pm, Wednesday, 13'th Aug 2025
Australian Cancer Trial Advances with First Cohort Complete, Amended Protocol, and Promising Preclinical Data Published; Operating Expenses Cut by 32% Conference Call to be Held Today at 4:30 p.m. ET
Aethlon Medical to Release Fiscal First Quarter Financial Results and Host Conference Call on August 13, 2025
08:01am, Tuesday, 05'th Aug 2025
SAN DIEGO , Aug. 5, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, to
SAN DIEGO , July 15, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a clinical-stage biotechnology company developing the investigational Aethlon Hemopurifier®, an extracorporeal device f
Aethlon Medical, Inc. (AEMD) Q4 2025 Earnings Call Transcript
07:35pm, Thursday, 26'th Jun 2025
Aethlon Medical, Inc. (NASDAQ:AEMD ) Q4 2025 Earnings Conference Call June 26, 2025 4:30 PM ET Company Participants James B. Frakes - CEO, CFO, Secretary & Director Conference Call Participants Anthon
Aethlon Medical Announces Financial Results for the Fiscal Fourth Quarter Ended March 31, 2025, and Provides Corporate Update
04:15pm, Thursday, 26'th Jun 2025
Three Patients Treated in Hemopurifier® Cancer Trial; Indian Regulatory Approval Achieved; Operating Expenses Reduced; R&D Advances Support Expanded Indications Including Long COVID Conference Call t
Aethlon Medical to Release Fiscal Fourth Quarter Financial Results and Host Conference Call on June 26, 2025
08:01am, Friday, 20'th Jun 2025
SAN DIEGO , June 20, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases,
Aethlon Medical Treats Second Patient in Australian Hemopurifier® Cancer Trial
08:01am, Wednesday, 18'th Jun 2025
Second Patient in first cohort enrolled and treated at the Royal North Shore Hospital/University of Sydney Aethlon Advances Hemopurifier® Study in Solid Tumors Not Responding to Anti-PD-1 Antibodies
